The Neurovascular Devices Market, estimated at USD 2.86 Bn in 2025, is expected to exhibit a CAGR of 4.1% and reach USD 3.79 Bn by 2032.
The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.
Increasing growth strategies, such as product launches, by key market players to expand their product portfolios are expected to drive the market growth over the forecast period. For instance, in December 2025, Terumo Corporation, a medical device company, announced the commercial launch of WEB Embolization System, an intrasaccular aneurysm treatment device in Japan. The WEB device is an intravascular device that can be used to treat intracranial wide neck bifurcation aneurysms that cannot undergo surgical clipping
Global Neurovascular Devices Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems with regard to the transportation of drugs from one place to another.
Neurovascular devices are required for surgeries for stroke and brain aneurysms, which might be delayed due to the pandemic. During the pandemic, brain surgeries were often being postponed or even cancelled. Moreover, neurosurgeons were faced various challenges such as treatment priority setting, ethical decision-making and risk of moral injury, as well as medico-legal risks, and financial uncertainties. For instance, according to a study published by National Center for Biotechnology Information in July 2025, neurosurgical care was negatively impacted by the COVID-19 pandemic. Elective surgical procedures were cancelled so that operating theater staff and operating equipment could be deployed for critical care. Outpatient activity was reduced in order to redirect resources and to lower transmission of the disease by decreasing the footfall in hospitals.
Global Neurovascular Devices Market: Key Developments
On June 27, 2025, MicroVention, Inc., a medical device company, announced the commercial launch of its Eric retrieval device in the U.S. for the treatment of ischemic stroke. Eric is a self-expanding laser-cut clot retriever with multiple retrieval cages, located on a pusher wire delivery system.
On May 2, 2025, Stryker, medical technology company, announced that it has completed the acquisition of Cerus Endovascular Ltd., a privately-held, commercial-stage, medical device company. Cerus Endovascular Ltd. engaged in the design and development of neurointerventional devices for the treatment of intracranial aneurysms.
On May 1, 2025, CERENOVUS, Inc., a part of Johnson & Johnson Service Inc.,a medical device company, announced the commercial launch of CEREPAK Detachable Coils in the U.S. CEREPAK Detachable Coils come in three shapes and multiple coil sizes, providing physicians with comprehensive options to embolize brain aneurysms, including coils shaped specifically to achieve concentric aneurysm filling and contribute large volumetric filling